Skip to main content

Prodesse to Remove Three ASRs From US Market, Submit Them for FDA OK

NEW YORK (GenomeWeb News) — Prodesse said today it will stop selling three of its multiplex ASR products in the US Aug. 1 as it transitions them into in vitro diagnostics in light of a recent US Food and Drug Administration draft guidance.
The company said it plans to remove the underlying supermixes for its Hexaplex, Hexaplex Plus, and ProPneumo-1 products as part of an “orderly transition” from ASRs to IVD assays.
“Though the actual ASR regulations have not changed, the September 2006 ASR draft guidance documents clearly show that the FDA’s posture towards ASRs has changed,” Prodesse CEO Tom Shannon said in a statement.
”Our company prefers to clear up any ambiguity in our customers' minds by moving from ASRs to IVDs,” Shannon added.
The company said its ProFlu+ test for influenza A, B, and RSV has completed clinical trials and a 510(k) application will “shortly” be submitted for FDA clearance.
The FDA has also received a pre-IDE submission on Prodesse’s Pro hMPV+ test for human metapneumovirus. More studies are in the planning stages, Prodesse said.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.